Clarus Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clarus therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clarus Therapeutic Today - Breaking & Trending Today

Financial Analysis: Clarus Therapeutics (OTCMKTS:CRXTQ) and AVROBIO (NASDAQ:AVRO)

AVROBIO (NASDAQ:AVRO – Get Free Report) and Clarus Therapeutics (OTCMKTS:CRXTQ – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability. Institutional & Insider Ownership 60.0% of AVROBIO shares […] ....

United States , United Kingdom , Avrobio Inc , Clarus Therapeutics Holdings Inc , Get Free Report , Clarus Therapeutics , Clarus Therapeutic , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Nasdaq Avro , Stock Comparison , Stock Analysis ,

Global Hormone Replacement Therapy Market to Surpass US$

Seattle, July 27, 2022 (GLOBE NEWSWIRE) According to Coherent Market Insights, the global hormone replacement therapy market is estimated to be valued. ....

United States , United Kingdom , South Africa , South Korea , Asia Pacific , Eli Lilly , Novo Nordisk , Bayer Ag , National Center , Route Of Administration Oral , Drug Administration , Teva Pharmaceutical Industries Ltd , Quatrx Pharmaceuticals , Merck Kga , Pfizer Inc , Amgen Inc , Merck Kgaa , Abbott Laboratories , Therapeuticsmd Inc , Coherent Market Insights , Global Hormone Replacement Therapy Market , Biotechnology Information , Testosterone Replacement Therapy , Clarus Therapeutic , Market Takeaways , Research Report ,

Analysts Expect Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Will Post Earnings of -$0.86 Per Share

Analysts expect Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) to announce ($0.86) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Clarus Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.13) and the highest estimate coming in at ($0.59). The business is […] ....

United States , Thomson Reuter , Schonfeld Strategic Advisors , Powell Investment Advisors , Clarus Therapeutics Company Profile Get Rating , Zacks Investment Research , Needham Company , Verition Fund Management , Clarus Therapeutics Holdings Inc , Clarus Therapeutics Holdings , Get Rating , Clarus Therapeutic , Clarus Therapeutics , Investment Research , Fund Management , Investment Advisors , Therapeutics Company Profile , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Nasdaq Crxt ,

Analysts Expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) Will Post Earnings of -$0.86 Per Share

Analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to report earnings of ($0.86) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($1.13). The firm is scheduled to report its next earnings […] ....

Schonfeld Strategic Advisors , Powell Investment Advisors , Clarus Therapeutics Company Profile Get Rating , Zacks Investment Research , Needham Company , Blue Water Acquisition Corp , Citadel Advisors , Clarus Therapeutics Holdings Inc , Clarus Therapeutics Inc , Get Rating , Clarus Therapeutic , Clarus Therapeutics , Investment Research , Strategic Advisors , Investment Advisors , Therapeutics Company Profile , Therapeutics Inc , Nasdaq Crxt ,

Zacks: Analysts Anticipate Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) Will Post Quarterly Sales of $5.30 Million

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock. ....

Schonfeld Strategic Advisors , Powell Investment Advisors , Clarus Therapeutics Company Profile Get Rating , Zacks Investment Research , Needham Company , Verition Fund Management , Blue Water Acquisition Corp , Citadel Advisors , Clarus Therapeutics Holdings Inc , Clarus Therapeutics Inc , Wall Street , Get Rating , Zacks Investment , Clarus Therapeutic , Clarus Therapeutics , Investment Research , Strategic Advisors , Investment Advisors , Therapeutics Company Profile , Therapeutics Inc ,